When is the HAV vaccine indicated in the management of HIV infection in primary care?

Updated: Apr 09, 2019
  • Author: Jason F Okulicz, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Answer

Answer

Administer to susceptible MSM, as well as others with indications for hepatitis A virus vaccine. Revaccinate in 6-12 months for Havrix or 6-18 months for Vaqta. Vaccine is also available in combination with hepatitis B vaccine as Twinrix, administered as 3 or 4 doses. Serologic response should be checked 1 month after completion of series, and nonresponders should be revaccinated.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!